source
- FDA flags potential VEGF-related safety concern in Summit rejection letterThe FDA flagged a safety issue in its review of Summit Therapeutics’ and Akeso's now-rejected cancer drug ivonescimab, raising questions about the viability of the whole class of new bispecifics, t…Endpoints · 25m ago↗ source
- FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines WorldwideFDA today announced the Global Reliance Disclosure Program (GRDP), a landmark initiative that will fundamentally transform how the FDA's regulatory drug and biologic approval decisions are leverage…fda press · 28m ago↗ source
- Beren wins FDA approval for long-studied rare disease drugA molecule designed by government scientists more than a decade ago has won FDA approval to treat infantile-onset Niemann-Pick disease type C, capping a winding and rocky development path. Beren Th…